Search Within

Tiffany A Traina

  1. "Body Imaging Service"
Formats
  1. Meeting Abstract (17)
  2. Journal Article (4)
Groups
  1. Body Imaging Service (21)
  2. Breast Medicine Service (21)
  3. Department of Medicine (21)
  4. Radiology, Department of (21)
  5. Solid Tumor Oncology Division (21)
  6. Survivorship Research (21)

More Groups

People
  1. Clifford Hudis (17)
  2. Sujata Patil (15)
  3. Kimberly Feigin (14)
  4. Larry Norton (9)
  5. Maria Theodoulou-Haber (9)
  6. Ayca Gucalp (7)

More People

Years
  1. 2022 (1)
  2. 2021 (1)
  3. 2020 (1)
  4. 2018 (1)
  5. 2016 (1)
  6. 2015 (1)

More Years

Publications
  1. Journal of Clinical Oncology (9)
  2. Cancer Research (5)
  3. International Journal of Radiation Oncology, Biology, Physics (2)
  4. Annals of Oncology (1)
  5. Breast Cancer Research and Treatment (1)
  6. Cancer (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (9)
  2. American Association for Cancer Research (6)
  3. Elsevier Inc. (3)
  4. Oxford University Press (1)
  5. Springer (1)
  6. Wiley Blackwell (1)

Results (21)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A novel capecitabine schedule (7 on—7 off) is feasible with lapatinib for patients with HER2-positive metastatic breast cancer refractory to trastuzumab
    Meeting Abstract

    Gajria, D.; Theodoulou, M.; Feigin, K.; Patil, S.; Geneus, S.; Drullinsky, P.; D'Andrea, G.; Lake, D.; Norton, L.; Hudis, C.; more...
    Cancer Research (2010)

    Fulltext@MSK | Save
  • Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer
    Journal Article

    Conlin, A.; Seidman, A.; Bach, A.; Lake, D.; Dickler, M.; D'Andrea, G.; Traina, T.; Danso, M.; Brufsky, A.; Saleh, M.; more...
    Clinical Breast Cancer (2010)

    Fulltext@MSK | Save
  • Safety of a novel capecitabine dosing schedule when combined with lapatinib in patients with HER2-positive metastatic breast cancer refractory to trastuzumab
    Meeting Abstract

    Traina, T. A.; Theodoulou, M.; Feigin, K.; Patil, S.; Geneus, S.; Modi, S.; Fornier, M.; Lake, D.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: A phase II study
    Meeting Abstract

    Traina, T. A.; Theodoulou, M.; Dugan, U.; Feigin, K.; Patil, S.; Geneus, S.; Godfrey, L.; Norton, L.; Hudis, C.
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Androgen receptor inhibition can stabilize disease in patients with AR(+), ER(-)/PR(-) metastatic breast cancer
    Meeting Abstract

    Traina, T. A.; Feigin, K.; Patil, S.; Yuan, J.; Dickler, M.; Andrea, G. D.; Bromberg, J.; Hudis, C.
    Annals of Oncology (2009)

    Fulltext@MSK | Save
  • Phase II study of weekly nanoparticle albumin bound (nab)paclitaxel with carboplatin and trastuzumab as 1st-line therapy for HER2-positive metastatic breast cancer (MBC)
    Meeting Abstract

    Seidman, A. D.; Conlin, A. K.; Bach, A.; Brufsky, A. M.; Saleh, M. N.; Lake, D.; Dickler, M. N.; D'Andrea, G.; Traina, T. A.; Hudis, C. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: A phase II study
    Meeting Abstract

    Traina, T. A.; Theodoulou, M.; Dugan, U.; Feigin, K.; Patil, S.; Edwards, C.; Norton, L.; Hudis, C. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer
    Journal Article

    Traina, T. A.; Theodoulou, M.; Feigin, K.; Patil, S.; Tan, L. K.; Edwards, C.; Dugan, U.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Phase I study of a novel capecitabine schedule based on Norton-Simon mathematical modeling
    Meeting Abstract

    Theodoulou, M.; Traina, T. A.; Dugan, U.; Lake, D.; Fornier, M.; Feigin, K.; Patil, S.; Edwards, C.; Norton, L.; Hudis, C. A.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer: An initial interim safety report
    Meeting Abstract

    Conlin, A. K.; Seidman, A. D.; Moynahan, M. E.; Traina, T.; Mace, J. R.; Meiri, E.; Bach, A.; Edwards, C.; Hudis, C. A.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save